Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125188 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL1079321 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL30812783 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL597672 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL2509 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL30307036 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL30671620 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| Benzene SCHEMBL9751882 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL3409457 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 | |
| SCHEMBL9871011 | 0.87 | TSHR (0.94) | TSHRSMN1; SMN2POLBCYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101987891-B | Polyolefin resin and nucleating agent-containing composition | CHINA PETROLEUM & CHEMICAL | 2013-04-10 | — | — | CN | claimed |
| CN-101987891-A | Polyolefin resin and nucleating agent-containing composition | CHINA PETROLEUM & CHEMICAL | 2011-03-23 | — | — | CN | claimed |
| US-9643971-B2 | Breathing control modulating compounds, and methods of using same | GALLEON PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| CN-106536523-A | Expedient synthesis of sitagliptin | 斯特里奥肯公司 | 2017-03-22 | — | — | CN | disclosed |
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| EP-2968329-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151462-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| CN-101830803-B | Method for synthesizing citric acid ester type compound | UNIV NORTHWEST NORMAL | 2013-04-03 | — | — | CN | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| CN-101830803-A | Method for synthesizing citric acid ester type compound | UNIV NORTHWEST NORMAL | 2010-09-15 | — | — | CN | disclosed |
| US-5262446-A | Resin acid, esters or abietyl phthalate foaming agent | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, LDLR, PCSK9 | TSHR 1637/4885SMN1; SMN2 4854/4885POLB 3099/4885 |
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | PRDX5, QDPR, P2RX5 | TSHR 3814/4885SMN1; SMN2 378/4885POLB 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.